Hematologic Malignancy
Mature B-Cell Neoplasm
CI-CAN-00003258Explore in graph →
HematologicNon-malignant1,787 active trials44 approved drugs119 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003258Explore in graph →
Clinical trials
6,664 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02396134 | Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant | completed | Phase 2 | 61 | City of Hope Medical CenterOTHER | 1 | Mar 3, 2025 | clinicaltrials |
| NCT03484819 | Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Mar 3, 2025 |
| clinicaltrials |
| NCT01437709 | Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant | completed | Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT04080531 | Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders | completed | Phase 4 | 165 | Emory UniversityOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT04312841 | Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab | completed | Phase 2 | 6 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT04999085 | Geriatric-assessment Interventions to Address Functional Deficits in Older Adults w Multiple Myeloma | completed | N/A | 16 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT04872413 | Interrogating Biological Signaling Pathway Dysregulations and In Vitro Screening With Personalized Therapies in Relapsed or Refractory Mantle Cell Lymphoma, MCL MATCH Trial | completed | N/A | 1 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 26, 2025 | clinicaltrials |
| NCT05131815 | The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors | completed | N/A | 8 | Cedars-Sinai Medical CenterOTHER | 1 | Feb 26, 2025 | clinicaltrials |
| NCT04537715 | Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels | completed | Phase 1 | 42 | Epizyme, Inc.INDUSTRY | 2 | Feb 19, 2025 | clinicaltrials |
| NCT05243342 | A Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Participants With Relapsed/Refractory Multiple Myeloma | completed | Phase 1 | 18 | Genentech, Inc.INDUSTRY | 4 | Feb 17, 2025 | clinicaltrials |
| NCT03732703 | Myeloma-Developing Regimens Using Genomics (MyDRUG)(MyDRUG) | completed | Phase 1 / Phase 2 | 103 | Multiple Myeloma Research ConsortiumNETWORK | 1 | Feb 14, 2025 | clinicaltrials |
| NCT02921893 | Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome | completed | Early Phase 1 | 21 | Mayo ClinicOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT03088878 | A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies | completed | Phase 1 / Phase 2 | 95 | Oncternal Therapeutics, IncINDUSTRY | 1 | Feb 12, 2025 | clinicaltrials |
| NCT03792763 | Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients(DEFENCE) | completed | Phase 2 | 8 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 3 | Feb 11, 2025 | clinicaltrials |
| NCT01638533 | Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction | completed | Phase 1 | 37 | National Cancer Institute (NCI)NIH | 2 | Feb 7, 2025 | clinicaltrials |
| NCT02245867 | Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis | completed | Phase 1 | 30 | Alexion Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 7, 2025 | clinicaltrials |
| NCT03398200 | Effects of Hyperbaric Oxygen (HBO) on Blood Count Recovery After Autologous Hematopoietic Stem Cell (HSPC) Transplant for Multiple Myeloma | completed | Phase 2 | 99 | Omar AljitawiOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT03992339 | A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma(SEARCH) | completed | Phase 2 | 60 | Antengene CorporationINDUSTRY | 1 | Feb 7, 2025 | clinicaltrials |
| NCT03762291 | Multiple Myeloma Trial of Orally Administered Salmonella Based Survivin Vaccine(MAPSS) | completed | Phase 1 | 1 | Baylor College of MedicineOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT01539083 | Velcade (Bortezomib) Consolidation After Transplant(VCAT) | completed | Phase 3 | 256 | Janssen Scientific Affairs, LLCINDUSTRY | 3 | Feb 4, 2025 | clinicaltrials |
| NCT02874742 | Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 224 | Janssen Research & Development, LLCINDUSTRY | 1 | Feb 4, 2025 | clinicaltrials |
| NCT03357952 | A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma | completed | Phase 2 / Phase 3 | 10 | Janssen Research & Development, LLCINDUSTRY | 3 | Feb 4, 2025 | clinicaltrials |
| NCT04599634 | Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies | completed | Phase 1 | 11 | National Cancer Institute (NCI)NIH | 1 | Feb 4, 2025 | clinicaltrials |
| NCT03476655 | Clinical Outcomes of Chronic Lymphocytic Leukemia (CCL) and Mantle Cell Lymphoma (MCL) Participants Treated With Ibrutinib: A Medical Chart Review From India | completed | — | 40 | Johnson & Johnson Private LimitedINDUSTRY | 1 | Feb 3, 2025 | clinicaltrials |
| NCT03768960 | A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent | completed | Phase 4 | 150 | Johnson & Johnson Private LimitedINDUSTRY | 1 | Feb 3, 2025 | clinicaltrials |
| NCT05986682 | Real-World Analysis of Belantamab Mafodotin Care Patterns in Patients With Relapsed and/or Refractory Multiple Myeloma | completed | — | 30 | Duke UniversityOTHER | 1 | Feb 3, 2025 | clinicaltrials |
| NCT03187223 | Bendamustine and Melphalan in Myeloma(BEB-2) | completed | Phase 2 | 120 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT01718743 | Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 64 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT04432506 | Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma | completed | Phase 2 | 22 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT05529524 | Signatures of Response and Resistance to Mosunetuzomab in Follicular Lymphomas (FL) | completed | — | 6 | The Lymphoma Academic Research OrganisationOTHER | 1 | Jan 24, 2025 | clinicaltrials |
| NCT03263026 | Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™ | completed | Phase 3 | 256 | Denovo Biopharma LLCINDUSTRY | 2 | Jan 23, 2025 | clinicaltrials |
| NCT04634435 | Autologous Memory-like NK Cell Therapy With BHV-1100 and Low Dose IL-2 in Multiple Myeloma Patients | completed | Phase 1 | 7 | Biohaven Pharmaceuticals, Inc.INDUSTRY | 1 | Jan 20, 2025 | clinicaltrials |
| NCT04890236 | Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study | completed | Early Phase 1 | 4 | Emory UniversityOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06782854 | Understanding the Role of Large Extracellular Vesicles in Lymphomas and Lymphoproliferative Disorders: the "Off the Beaten Track" Liquid Biopsy | completed | — | 102 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT02990338 | Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients(ICARIA-MM) | completed | Phase 3 | 307 | SanofiINDUSTRY | 24 | Jan 17, 2025 | clinicaltrials |
| NCT03870633 | Assessment of Financial Difficulty in Participants with Chronic Lymphocytic Leukemia and Multiple Myeloma | completed | — | 521 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jan 17, 2025 | clinicaltrials |
| NCT04135079 | Immune Profiling in Multiple Myeloma | completed | — | 50 | Mario BoccadoroOTHER | 1 | Jan 16, 2025 | clinicaltrials |
| NCT04716075 | Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)(ACALLO) | completed | Phase 2 | 29 | Polish Lymphoma Research GroupNETWORK | 1 | Jan 16, 2025 | clinicaltrials |
| NCT05393024 | Patient With MMRR Treated With Belantamab Mafotidine on Monotherapy | completed | — | 78 | Fondazione EMN Italy OnlusOTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT06777290 | Comparison of Whole-body MRI, Circulating DNA and PET-CT in Staging, Prognosis, and Treatment Response in Patients with Diffuse Large Cell B Lymphoma | completed | — | 14 | Charles University, Czech RepublicOTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT04191057 | Determining Normal Range for Free Light Chains in Serum Among Twins | completed | N/A | 32 | University of California, San FranciscoOTHER | 1 | Jan 14, 2025 | clinicaltrials |
| NCT03773107 | LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 12 | Wake Forest University Health SciencesOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT00769522 | FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia | completed | Phase 3 | 564 | German CLL Study GroupOTHER | 1 | Dec 31, 2024 | clinicaltrials |
| NCT02863718 | Ibrutinib in Previously Untreated Binet Stage A Chronic Lymphocytic Leukemia With Risk of Disease Progression(CLL12) | completed | Phase 3 | 515 | German CLL Study GroupOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT03997968 | A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 169 | Cyteir Therapeutics, Inc.INDUSTRY | 1 | Dec 24, 2024 | clinicaltrials |
| NCT01903811 | S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma | completed | Phase 2 | 143 | SWOG Cancer Research NetworkNETWORK | 1 | Dec 20, 2024 | clinicaltrials |
| NCT02112526 | Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma | completed | Phase 1 | 21 | Acerta Pharma BVINDUSTRY | 2 | Dec 20, 2024 | clinicaltrials |
| NCT04028479 | The Registry of Oncology Outcomes Associated With Testing and Treatment(ROOT) | completed | — | 167 | Taproot HealthINDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
Data updated 24 days agoSource updated Mar 3, 2025source: clinicaltrials